<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971863</url>
  </required_header>
  <id_info>
    <org_study_id>ASQM012021</org_study_id>
    <nct_id>NCT04971863</nct_id>
  </id_info>
  <brief_title>In-vivo Behavior of Asqelio Monofocal Biaspheric Intraocular Lens</brief_title>
  <official_title>In-vivo Behavior of Asqelio Monofocal Biaspheric Intraocular Lens. Two-year Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AST Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AST Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the 24 month postoperative incidence and intensity of posterior&#xD;
      capsular opacity in patients submitted to cataract surgery and implanted with a hydrophobic&#xD;
      monofocal IOL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a two-arm masked clinical evaluation study of incidence of PCO after successful&#xD;
      bilateral cataract surgery with implantation of a monofocal IOL. Subjects will be assessed 24&#xD;
      months after IOL implantation. Clinical evaluations will include incidence of adverse events,&#xD;
      patient satisfaction questionnaire, as well as measurements of visual performance, optical&#xD;
      quality, presence and intensity of PCO, presence and intensity of IOL glistening.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Posterior capsular opacity</measure>
    <time_frame>24 months after IOL implantation</time_frame>
    <description>Incidence of PCO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of Posterior capsular opacity</measure>
    <time_frame>24 months after IOL implantation</time_frame>
    <description>Intensity of PCO determined using LOCSIII Classification System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 month, 6 months, 12 months and 24 months after IOL implantation</time_frame>
    <description>Best corrected distance visual acuity in LogMAR units using the ETDRS chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refraction</measure>
    <time_frame>1 month, 6 months, 12 months and 24 months after IOL implantation</time_frame>
    <description>Residual refractive error in diopters determined objectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical quality</measure>
    <time_frame>24 months after IOL implantation</time_frame>
    <description>Higher-order wavefront aberrations determined using a clinical wavefront analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Glistening</measure>
    <time_frame>24 months after IOL implantation</time_frame>
    <description>Incidence of IOL glistening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Glistening</measure>
    <time_frame>24 months after IOL implantation</time_frame>
    <description>Intensity of IOL glistening</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cataract</condition>
  <condition>Intraocular Lens Complication</condition>
  <arm_group>
    <arm_group_label>Clareon Monofocal IOL</arm_group_label>
    <description>Patients bilaterally implanted with the Clareon monofocal IOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asqelio Monofocal IOL</arm_group_label>
    <description>Patients bilaterally implanted with the Asqelio monofocal IOL</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects submitted to non-traumatic cataract surgery in at least 1 eye at the&#xD;
        Hospital La Fé of Valencia, Spain&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects 22 years or older submitted to cataract surgery in at least 1 eye and&#xD;
             implanted with Asqelio monofocal or Clareon monofocal IOL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any pathology reducing potential best-corrected visual acuity beyond 0.30 LogMAR,&#xD;
             including amblyopia, severe corneal dystrophy, diabetic retinopathy, extremely shallow&#xD;
             anterior chamber, microphthalmos, retinal detachment, severe recurrent anterior or&#xD;
             posterior segment inflammation of unknown ethiology, iris neovascularization,&#xD;
             uncontrolled glaucoma, clinically significant macular degeneration, or&#xD;
             pseudoexfoliation diagnosis.&#xD;
&#xD;
          -  Previous ocular surgery&#xD;
&#xD;
          -  Rubella&#xD;
&#xD;
          -  Surgery motivated by traumatic cataract&#xD;
&#xD;
          -  Ocular trauma or refractive surgery&#xD;
&#xD;
          -  Any other systemic or ocular condition that, in the investigator's opinion, should&#xD;
             exclude the subject from study&#xD;
&#xD;
          -  Requiring additional procedures due to intraoperatory complications, mechanical or&#xD;
             surgical interventions for manipulating the pupil, excessive iris movility,&#xD;
             significant vitreous loss, significant, anterior chamber hyphema, capsular annular&#xD;
             breakage, or any other unrecognized ocular conditions that might compromise IOL&#xD;
             positioning, as well as impossibility of locate the IOL in the capsular bag due to&#xD;
             surgical complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AST Products, Inc.</last_name>
    <phone>9786674500</phone>
    <email>inquiry2019@astp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>posterior capsule opacitication</keyword>
  <keyword>incidence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

